Ebola vaccines: Candidates, trials and rollout timeline

Ebola vaccines under accelerated development

Ebola vaccines are racing through clinical pipelines as the West African outbreak outpaces containment efforts. Three primary candidates—Merck’s rVSV‑ZEBOV, Johnson & Johnson’s Ad26.ZEBOV/MVA‑BN‑Filo, and Inovio’s DNA platform—have secured emergency funding and are moving at breakneck speed.

Merck’s rVSV‑ZEBOV entered Phase III last month, enrolling ↑ 70% more volunteers than initially planned, according to Reuters. The trial aims for regulatory submission by early 2027.

Johnson & Johnson’s duo‑vector regimen is in a combined Phase II/III study across four nations. A ↓ $15 million funding gap could delay results, a risk highlighted by AP News.

“Accelerated pathways are essential, but safety cannot be compromised,” said a WHO spokesperson.

Must Read Intel Read the full classified report →

Related Intel: Will AI Prior Authorization Streamline Care or Deepen Denials?

Should any candidate receive licensure, mass‑vaccination campaigns could commence within 18 months of approval, echoing lessons learned during the recent pandemic. Stakeholders remain vigilant as the virus spreads.